BIO-Europe – PERMIDES Digital Health Forum
The PERMIDES consortium will organise a Digital Health Forum within the BIO-Europe Conference, focusing on latest issues in the field of BioPharma and Personalized Medicine.
PERMIDES will be part of the Digital Health Day Nov 8th
Advancing precision medicine via novel digital solutions
In an era of precision medicine, massive amounts of structured and unstructured data are accumulated per patient. The amount of medical data is expected to double every 73 days by 2020. Big Data is becoming a major topic for the biopharma industry, despite a low level of digitization compared to other sectors. Adopting digital technologies is a prerequisite for gaining actionable insights from health and disease related data and to deliver on the promises of precision medicine. Global tech companies are investing heavily into novel ventures and initiatives and big pharma is scaling up their digitalization efforts. Smaller players such as start-ups and biotechs have limited resources and capabilities to implement novel digital solutions. However, they need to do so to advance and improve their R&D efforts. The PERMIDES EU Project aims to accelerate the digitalization of biopharma SMEs via connecting them to suitable bioinformatics and IT partners and funding joint innovation projects. The session will discuss trends, challenges and opportunities associated with the digitalization of the biopharma value chain. Speakers with complementary backgrounds and expertise will share their insights and discuss with SMEs pitching their case studies and innovation projects facilitated via PERMIDES.
Bio-Europe the “must-attend” event is Europe’s largest life science partnering conference.
“BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop and panel participation, a high profile exhibition, and private, prescheduled one-to-one meetings.
Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
The BIO-Europe 2017 partnering event is expected to draw over 3,800 industry attendees for three days of high level networking, representing upwards of 2,000 companies from over 60 countries.”